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Traumatic brain injury (TBI) can cause seizures and the development of epilepsy. The
incidence of seizures varies from 21% in patients with severe brain injuries to 50% in
patients with war-related penetrating TBI. In the acute and sub-acute periods following
injury, seizures can lead to increased intracranial pressure and cerebral edema, further com-
plicating TBI management. Anticonvulsants can be used for seizure prophylaxis according
to the current Parameters of Practice and Guidelines in a subset of severe TBI patients,
and for a limited time window. Phenytoin is the most widely prescribed anticonvulsant in
these patients. Intravenous levetiracetam, made available in 2006, is now being consid-
ered as a viable option in acute care settings if phenytoin is unavailable or not feasible due
to side-effects.We discuss current data regarding the role of intravenous levetiracetam in
seizure prophylaxis of severe TBI patients and the need for future studies.
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INTRODUCTION
POST TRAUMATIC SEIZURES
The annual incidence of traumatic brain injury (TBI) is 1.7 mil-
lion in the United States (1). One well-recognized complication of
moderate to severe TBI is post traumatic seizure (PTS). A study
by Temkin et al. shows a 2-year seizure rate of 21% after severe
TBI (2). In another study by Salazar et al. the incidence of seizures
is almost 50% after penetrating war-related TBI (3). It is gener-
ally accepted that mild TBI or concussion can increase the risk
of developing epilepsy but the incidence is uncertain. This uncer-
tainty is largely due to incomplete knowledge of the incidence of
mild TBI itself.
Post traumatic seizure are divided into two subgroups. The
seizures occurring within the first 7 days after brain injury are
classified as early PTS. Those occurring after 7 days of injury are
classified as late PTS. Non-convulsive electrographic seizures can
also occur. These can lead to cerebral metabolic crisis, delayed
increase in intracranial pressure, and worse clinical outcome (4).
The deleterious effects of PTS exacerbate the existing brain
injury and contributes to greatly worse TBI outcome. Conse-
quently, an important clinical goal in TBI care is preventing
seizures. To this end, Temkin et al. conducted a series of random-
ized placebo controlled trials (RCT) that demonstrated efficacy
of phenytoin, valproate, and carbamazepine in reducing the inci-
dence of early PTS (2, 5, 6). These same studies showed that there
was no benefit for late PTS.
Phenytoin is the preferred agent of choice for early PTS prophy-
laxis. It is generally well tolerated, can be administered once per
day, can be given IV and most medical practitioners are familiar
with its use. Valproate is less desirable as it is shown to be associ-
ated with increased mortality. Carbamazepine is not yet clinically
available in an IV formulation. This issue is important because
most moderate to severe TBI patients cannot take medications
orally due to inability to protect their airways. Thus, valproate and
carbamazepine should be considered as alternatives to phenytoin
for early PTS prophylaxis (7, 8).
Phenytoin has significant adverse effects. The most common are
hypersensitivity reactions, irritation of the skin, phlebitis, arrhyth-
mias, and hypotension during parenteral administration (9). One
particularly severe toxicity is Stevens Johnson Syndrome. Pheny-
toin has a narrow therapeutic index and non-linear kinetics so a
small increase in dose may result in much greater increase in levels
resulting in toxicity. Additionally, it is more prone to drug–drug
interactions because of the induction of the hepatic cytochrome
P450 system which further limits its use in critically ill patients
(10). Phenytoin has also been shown to exacerbate acute adrenal
hyporesponsiveness, a phenomenon seen in patients with severe
brain injury by decreasing the cortisol concentration (11–14). A
limitation frequently encountered with phenytoin is the use of
weight based dosing, which often leads to subtherapeutic levels of
the drug (15).
Because of these complications and the limitations of valproate
and carbamazepine, levetiracetam is more often being considered
as a viable option.
Intravenous levetiracetam was approved by the FDA in 2006
and has a number of advantages over phenytoin. Levetiracetam
has linear pharmacokinetics (PKs) and is thus easier to titrate.
It has lower potential of drug–drug interaction than phenytoin.
It has not yet been shown to have enzyme inducing properties.
Finally, there is no need to monitor of serum drug levels (16). In
this review, we will discuss the studies which provide evidence of
efficacy of intravenous levetiracetam in the prevention of PTS.
Preclinical studies using animal models of TBI have shown
efficacy of levetiracetam as a neuroprotectant. Zou et al. report
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a study of rats treated with levetiracetam after receiving a con-
trolled cortical impact (CCI) TBI. In this study, 50 mg/kg of either
intraperitoneal levetiracetam or saline control were administered
daily for 20 days starting 1 day after CCI or sham injury. To deter-
mine neurobehavior outcome, rats were tested on balance beam,
Y-maze, and the Morris Water Maze. Levetiracetam treatment was
shown to be beneficial to neurobehavior functional recovery and
hippocampal cell sparing. It also decreased contusion volumes by
almost 33%. Finally, TBI-induced decreases in regional glutamate
transporter expression and neuroplastic markers were reversed
by levetiracetam. The investigators concluded that levetiracetam
treatment post-TBI, lead to improved histological, molecular, and
neurobehavioral outcomes (17).
In spite of these promising preclinical studies, levetiracetam has
not yet been conclusively shown to have neuroprotective or neuro
rescue effects in humans.
However, there is human clinical evidence to show that lev-
etiracetam is a reasonable alternative to phenytoin for seizure
prophylaxis. In a prospective multicenter comparison of leve-
tiracetam vs. phenytoin for early PTS prophylaxis by Inaba and
colleagues, patients with closed head TBI are treated with either
medication. A total of 813 patients are analyzed of which 406
received levetiracetam and 407 received phenytoin. The two groups
are balanced for age, gender, Injury Severity Score (ISS), Marshall
score of ≥3 or craniectomy. There results reveal no statistically
significant difference in terms seizure rate, adverse drug reactions,
or mortality. The authors conclude that levetiracetam did as well
but not better than phenytoin as an early PTS prophylaxis. The
cost of Levetiracetam is higher than phenytoin and availability is
also an issue. However, the need and cost of monitoring favors
Levetiracetam (18).
For other than TBI brain pathological states, Zafar et al. report a
meta-analysis of studies that compare levetiracetam to phenytoin
for seizure prophylaxis for patients who suffer from TBI, intracra-
nial hemorrhage, intracranial neoplasms, and/or craniotomy. A
comprehensive electronic data search is performed on studies with
a primary outcome of seizures and have balanced the baseline pop-
ulation characteristics, type of intervention, and study design. Of
2489 studies, 8 meet inclusion criteria. Of these, two are RCT and
six observational studies. The results show odds ratio equal to 1.12
so there is no superiority of either agent in the prevention of early
seizures. The conclusion of the meta-analysis is that levetiracetam
and phenytoin have equal efficacy in seizure prevention after TBI
as well as intracranial hemorrhage, intracranial neoplasm, and
craniotomy. The limitation of this study is that the conclusions
are based on a few RCT. Thus, additional trials are recommended
(19).
Szaflarski et al. describe the first prospective randomized com-
parative trial of intravenous levetiracetam vs. phenytoin for seizure
prophylaxis in the neuro intensive care unit setting. Fifty-two
neuro intensive care unit patients are enrolled in this study. Many
(89%) have severe TBI. Thirty-four patients receive levetirac-
etam and 18 phenytoin. Standard intravenous doses are used with
doses of phenytoin adjusted to maintain therapeutic serum lev-
els. Continuous EEG monitoring is performed during first 72 h
of treatment. After controlling the baseline severity, there are bet-
ter outcomes with levetiracetam therapy as evidenced by lower
disability rating scales at 3 months and higher Glasgow outcomes
scales at 6 months. No differences in occurrence of seizures are
seen in either group during or at 6 months. No differences are
seen in adverse effects in either group except for lower incidence
of worsened neurological status and fewer gastrointestinal prob-
lems in the levetiracetam treated group. The authors conclude that
levetiracetam is a reasonable alternative to phenytoin for seizure
prophylaxis in the neuroscience ICU setting. The limitations of
this study include a small sample size, and a lack of reported data
on the use of sedating agents in these patients. Propofol is the
drug of choice in patients with severe TBI, which also has anticon-
vulsant properties. The concomitant use of both agents may have
confounded the results of the trial (20).
A retrospective, observational study is conducted by Kruer
et al. to evaluate patients treated with phenytoin vs. levetirac-
etam for seizure development within 7 days after TBI. Of 1,552
TBI patients identified through the adult trauma center registry,
354 met inclusion criteria of ≥3 on the Abbreviated Injury Scale
(AIS), and <8 on the Glasgow coma scale. A total of 245 patients
are excluded, mostly because no prophylactic antiepileptic drug
was given (34%) or there was no history of acute TBI (30%). The
remaining 109 adults who received phenytoin (N = 89) or lev-
etiracetam (N = 20) have additional information gathered from
the electronic medical record and paper chart. One patient in
each group had documented post-traumatic seizures. Sixty-five
percent of patients received prophylactic AEDs for >7 days, and
68/109 patients survived to hospital discharge. Between 2000 and
2007, nearly all of the patients (98%) received phenytoin. This was
reversed during 2008–2012 such that the majority (64%) patients
instead received levetiracetam. Thus, after FDA approval of its
IV formulation, a clinical trend favoring levetiracetam use over
phenytoin is observed but the lack of difference between these
drugs is due to the restricted results on PTS (21).
To determine efficacy for early PTS prophylaxis following severe
TBI, Jones et al. compare levetiracetam vs. phenytoin. The study is
conducted in 32 patients, all of whom receive IV levetiracetam for
the first 7 days after TBI. These data are compared to results from a
historical cohort of 41 patients who received phenytoin for seizure
prophylaxis. Patients are evaluated for 1 h by EEG if they have per-
sistent coma, decreased mental status, or clinical signs of seizures.
The results show that 15/32 patients in the levetiracetam group
and 12/41 in the phenytoin group require EEG monitoring. Of the
levetiracetam group, the EEG from seven patients were normal and
eight were abnormal. Of the EEG abnormal subgroup, one patient
had EEG evident seizure activity and the rest had signs of seizure
tendency but no overt evidence of seizure. The EEG results were
all normal in phenytoin treated patients. For seizure activity, there
was no statistical difference between these two treatment groups.
The authors conclude that levetiracetam is as effective as pheny-
toin in preventing early clinical PTS, but a higher incidence of
epileptogenicity with levetiracetam. The limitations of this study
included lack of randomization, small sample size, and duration
of the EEG recording. The rationale was that only 1-h record-
ings would not be able to capture actual seizures for which more
prolonged monitoring is required (22).
Studies have shown that the PK profile of intravenous leve-
tiracetam, which includes linear kinetics and lack of drug–drug
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interactions, favors this new agent over phenytoin. However, the
PK properties of levetiracetam are not etiology specific and more
studies are required in this subset of patients.
In a prospective, open-label, steady-state PK study by Spencer
and colleagues, steady-state PKs of IV LEV is assessed in neur-
ocritical care patients. The sample size of 12 adults, comprised
of five men and seven women aged 54± 14 years, all required
anticonvulsant prophylaxis in the neurocritical care unit after
TBI (N = 1), subarachnoid hemorrhage (N = 10), or subdural
hematoma (N = 1). Patients were eligible if they were >18 years
old, presence of arterial or central venous access for blood sam-
pling, and required IV LEV for seizure prophylaxis. Patients
were excluded if they had multisystem trauma, end-stage renal
disease, or hemoglobin concentration <7.0 g/dl. An IV infu-
sion of 500 mg LEV given over 15 min every 12 h was adminis-
tered to patients. After a minimum of four doses of LEV, serial
blood samples were collected from all patients. Ultraperformance
liquid chromatography with tandem mass spectrometry detec-
tion was used to determine the serum levetiracetam concentra-
tion. LEV maximum serum concentration was found to be a
mean± SD of 28.0± 8.0µg/ml, minimum serum concentration
3.1± 1.8µg/ml, and half-life 5.2± 1.2 h. The systemic clearance
was 5.6± 1.8 l/h and the volume of distribution at steady state
36.8± 6.3l. The probability of achieving a target trough con-
centration of 6µg/ml or greater was increased by greater doses
of LEV, but it also increased the probability of reaching trough
concentration greater than 20µg/ml. The highest probability of
achieving a target trough concentration of 6–20µg/ml was when
1,000 mg of LEV every 8 h and 1,500–2,000 mg every 12 h. The
authors concluded that the LEV systemic clearance was faster
and the terminal elimination half-life was shorter in neurocrit-
ical care patients than in previously reported results in adults in
status epilepticus or healthy volunteers. The study limitation is the
sample size (23).
Klein et al. conducts a fixed dose, open-label, non-randomized,
phase II safety, and PK study of patients, including children
≥6 years old, treated with levetiracetam after TBI with a high risk
of post-traumatic epilepsy. A total of 26 children and 15 adults are
enrolled,whose ages range from 6 to 87 years. TBI inclusion criteria
are any intracranial hemorrhage, except for isolated subarachnoid
hemorrhage or with penetrating wound injury, depressed skull
fracture, or early PTS. Beginning≤8 h after injury and lasting for a
duration of 30 days, all subjects receive levetiracetam 55 mg/kg/day
orally, nasogastrically, or intravenously. The initial dose is followed
by two divided doses every 12 h for the study duration. On treat-
ment days 3 and 30, all 41 subjects undergo PKs analysis. Thirty-six
of 41 subjects are randomized to undergo PK study on treatment
day 3, and 24/41 subjects are randomized to undergo PK study on
day 30. Mean Tmax on day 3 is 2.2 h, Cmax was 60.2µg/ml and
area under the curve (AUC) is 403.7µg/h/ml. Tmax is shorter in
children than in adults and elderly subjects (respectively, 1.5 and
1.8 vs. 5.96 h; p= 0.0001). Compared with adults and the elderly,
the AUC is non-significantly lower in children (461.4 and 450.2
vs. 317.4µg/h/ml). Cmax is non-significantly higher after admin-
istration IV (0.4µg/ml) vs. tablet (59µg/ml) or NG (48.2µg/ml).
AUC of IV and NG administration is 88 and 79% of the AUC
of oral administrations. Between days 3 and 30, the PKs are not
significantly different. The authors conclude that TBI study sub-
jects with a high PTS risk are treated with the same dose with
antiepileptogenic effect in animals (55 mg/kg/day) achieve plasma
LEV levels comparable to those in animal studies (24).
FUTURE DIRECTIONS
The available data have shown limitations and one cannot clearly
establish the efficacy and tolerability of intravenous levetiracetam
over phenytoin in early seizure prevention in severe TBI. Pheny-
toin still remains the drug of choice based on the existing evidence
and wide availability of PHT titration makes it easy to be managed
safely. However, based on the existing data, levetiracetam seems
to be a favorable choice for early seizure prophylaxis in patients
with severe TBI. Levetiracetam can be used in situations where
there is risk of drug–drug interactions and drug toxicity because
of the narrow therapeutic index of phenytoin. However, further
larger, prospective, randomized double blind multicenter trials are
needed to further define the role of this anticonvulsant in short
and long term seizure prophylaxis in patients with severe TBI.
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